This article is more than 5 years old. Information may no longer be current.

Triple therapy for CNV shows potential

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

RIO GRANDE, Puerto Rico — A treatment regimen that combines dexamethasone, anti-VEGF injection and photodynamic therapy is showing promising results at the 4-month follow-up in choroidal neovascularization patients with age-related macular degeneration, said one surgeon here.

Indre Offermann, MD, described the combination therapy to attendees of the Masters of the American Society of Retina Specialists meeting. A total of 46 patients have undergone the treatment so far, she said. All had either occult or classic lesions; the mean visual acuity at baseline was 20/100, and the mean age was 76.2 years old.

“We began with PDT, then added 1.25 mg of Avastin and 800 µg of dexamethasone,” she said. “With only one treatment cycle, the mean visual acuity increased 1.89 lines.”

By week 18, none of the patients had regressed to pre-treatment visual acuity, she said. None of the patients reported any side effects from the triple therapy, she added.

“We use dexamethasone instead of intravitreal triamcinolone because there’s less potential of an IOP spike,” she explained during a question and answer period.